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Abstract
Background: Although most guidelines recommend the use of cholinesterase inhibitors (ChEIs) for mild to moderate
Alzheimer’s Disease, only a small proportion of affected patients receive these drugs. We aimed to study if geriatric
comorbidity and polypharmacy influence the prescription of ChEIs in patients with dementia in Germany.
Methods: We used claims data of 1,848 incident patients with dementia aged 65 years and older. Inclusion criteria
were first outpatient diagnoses for dementia in at least three of four consecutive quarters (incidence year). Our
dependent variable was the prescription of at least one ChEI in the incidence year. Main independent variables
were polypharmacy (defined as the number of prescribed medications categorized into quartiles) and measures of
geriatric comorbidity (levels of care dependency and 14 symptom complexes characterizing geriatric patients). Data
were analyzed by multivariate logistic regression.
Results: On average, patients were 78.7 years old (47.6% female) and received 9.7 different medications (interquartile
range: 6-13). 44.4% were assigned to one of three care levels and virtually all patients (92.0%) had at least one
symptom complex characterizing geriatric patients. 13.0% received at least one ChEI within the incidence year.
Patients not assigned to the highest care level were more likely to receive a prescription (e.g., no level of care
dependency vs. level 3: adjusted Odds Ratio [OR]: 5.35; 95% CI: 1.61-17.81). The chance decreased with increasing
numbers of symptoms characterizing geriatric patients (e.g., 0 vs. 5+ geriatric complexes: OR: 4.23; 95% CI: 2.06-8.69).
The overall number of prescribed medications had no influence on ChEI prescription and a significant effect of age
could only be found in the univariate analysis. Living in a rural compared to an urban environment and contacts to
neurologists or psychiatrists were associated with a significant increase in the likelihood of receiving ChEIs in the
multivariate analysis.
Conclusions: It seems that not age as such but the overall clinical condition of a patient including care
dependency and geriatric comorbidities influences the process of decision making on prescription of ChEIs.
Background
International and national guidelines recommend the
use of cholinesterase inhibitors (ChEIs) for mild to mod-
erate Alzheimer’s disease [1-3]. Pharmacological treat-
ment with ChEIs has shown improvements in cognition
and activities of daily living [4]. However, the clinical
relevance of these treatment effects continues to be
questioned [5,6].
In Germany, the ChEIs donepezil and rivastigmine are
available since 1997 and 1998, and galantamine since
2001. Although in some countries donepezil is also
approved for use in severe Alzheimer’s dementia, in
Germany ChEIs are only approved for mild to moderate
Alzheimer’s disease. The prescription volumes of ChEIs
increased more than fivefold from 8.6 million defined daily
doses (DDD) in 2001 to 46.8 million DDD in 2009 [7,8].
An increase was especially found in older patients [9].
* Correspondence: hoffmann@zes.uni-bremen.de
1University of Bremen, Centre for Social Policy Research, Division Health
Economics, Health Policy and Outcomes Research, Bremen, Germany
Full list of author information is available at the end of the article
Hoffmann et al. BMC Psychiatry 2011, 11:190
http://www.biomedcentral.com/1471-244X/11/190
© 2011 Hoffmann et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Despite this rise of prescription volumes, the proportion of
dementia patients treated with ChEIs in Germany is still
low. Based on claims data of 2004-2006 van den Bussche
et al. found that 13% of patients with incident dementia
received ChEIs within the first year after diagnosis and
that less than half of those treated were prescribed an
appropriate dose [10]. Also based on administrative claims
in the Lombardy Region in Italy Franchi et al. found that
among estimated incident cases, the percentage of newly
treated patients with ChEIs dropped from 12% in 2004 to
8% in 2007 [11]. In a comparison of ChEI treatment preva-
lences in 2004 across nine European countries Pariente et
al. found a range between 3% in the Netherlands to 20% in
France [12]. They found 7% treated patients in Germany
and 6% in Italy, respectively. The authors attributed these
variations between countries to different health care and
reimbursement policies.
Factors promoting prescription of ChEIs found in the lit-
erature are younger age [11,13], living in a rural area in
Germany, a lower number of comorbid conditions [10],
contact with a neuropsychiatrist and a diagnosis of Alzhei-
mer’s disease in comparison to unspecified diagnoses and
other specific dementias [10,14]. Based on a knowledge
test Pentzek et al. stated that most general practitioners
are aware of the positive expectations surrounding anti-
dementia drugs, which are supposed to improve cognition
and activities of daily living and to slow down progression
[15]. However, for many physicians these expectations are
too optimistic and differ with their own experiences. Prob-
able factors impeding ChEI prescriptions have not yet been
studied systematically. They are not mutually exclusive and
refer to difficulties with the diagnosis of the dementia syn-
drome and type, presence of significant concurrent mor-
bidity, adverse drug reactions, and fatalistic acceptance of
the condition [13]. They all are positively related with age.
Multimorbidity, usually associated with polypharmacy,
may be the key to understanding the low prescription pre-
valences of ChEIs in patients with dementia. In the recent
dementia guideline of the German College of General
Practitioners and Family Physicians, multimorbidity is
even listed as a potential reason for not further investigat-
ing the suspicion of dementia [16]. This must have impli-
cations for diagnosis, disclosure and treatment. However,
the role of geriatric comorbidity and polypharmacy in the
prescription of ChEIs has not yet been studied systemati-
cally. Therefore the main question of this study is:
Do geriatric comorbidity and polypharmacy influence
the prescription of ChEIs in patients with dementia in
Germany?
Methods
Design and study population
We used claims data of a cohort of 1,848 patients with
incident dementia, which is described in detail elsewhere
[10,17-19]. In brief, these patients were drawn from the
Gmünder ErsatzKasse (GEK), a statutory health insur-
ance company which insured 1.7 million people located
in all regions of Germany (2% of the German popula-
tion). We included only patients with a first diagnosis of
dementia in outpatient care between the first quarter of
the year 2005 and the first quarter of 2006. All patients
included had a period free from this diagnosis of at least
4 quarters before the first quarter with such a code.
Quarters had to be chosen because they form the basic
time period for coding diagnoses in outpatient care in
Germany. Patients were included if the following criteria
were fulfilled:
￿ age of at least 65 years,
￿ at least one ICD-10 code for dementia from the
following list (F00.x, F01.x, F02.0, F02.3, F03, G30.x,
G31.0, G31.1, G31.82, G31.9, and R54) in outpatient
care in at least 3 of 4 consecutive quarters,
￿ continuous insurance period in the year before and
after the first code was recorded.
The quarter in which one of the codes appears for the
first time is called the ‘incidence quarter’. This and the fol-
lowing 3 quarters are referred to as the ‘incidence year’.
For this study, we used claims data for the incidence year.
Cholinesterase inhibitors and covariates
Our dependent variable was at least one prescription of
any of the three cholinesterase inhibitors (donepezil, rivas-
tigmine, galantamine) in the incidence year. Our main
independent variables were polypharmacy and measures
of geriatric comorbidity. The concurrent use of multiple
drugs is often termed polypharmacy, but there is no
accepted international definition of this concept [20-22].
However, such a definition might be difficult because it
has to be applied to different age groups, index diseases or
populations. Therefore, we categorized the number of pre-
scribed medications in our cohort into quartiles and oper-
ationalized polypharmacy in each patient (0-25%, 26-50%,
51-75% and 76-100%).
We used two measures of geriatric comorbidity: (1)
data of the long term care insurance and (2) symptom
complexes characterizing geriatric patients. Services from
the German long term care insurance are provided to
those who require support in the activities of daily living
including personal hygiene, eating, mobility and - sepa-
rate from personal care - housekeeping. There are three
levels of care dependency related to the estimated time
required for assistance indicating moderate (level 1),
severe (level 2) and severest care dependency (level 3)
[23,24]. If care dependency changed within the incidence
year we considered the highest level in our analyses.
Symptom complexes characterizing geriatric patients
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tric associations in Germany. For instance, these 15 com-
plexes include amongst others incontinence, risk of falls
and dizziness, pressure ulcer as well as severe visual dis-
turbances and hearing loss. We did not consider cogni-
tive deficits since all of our patients would fulfil this
criterion. The corresponding ICD-10 codes are published
in Borchelt et al. [25] (see Table 1). Outpatient diagnoses
documented in the incidence year (at least one quarter
with a corresponding ICD-code) were used to assign the
respective number of symptom complexes to each patient -
characterizing his or her geriatric comorbidity.
We included sex and age as further independent vari-
ables. A dichotomous regional variable indicating living
in an urban or rural area was created based on municipa-
lities. The procedure of constructing this variable is
described elsewhere [18]. We further assessed the num-
ber of physician contacts with neurologists and psychia-
trists in the incidence year.
Statistical analysis
After a descriptive characterization of the study cohort,
the proportion of patients with at least one prescription
of ChEIs was estimated. To study the relation between
the prescription of ChEIs and polypharmacy, measures of
geriatric comorbidity as well as other covariates, we fitted
logistic regression models. First, univariate analyses were
performed to determine the association between prese-
lected variables and prescribing (model 1). The following
variables were included: age (65-74, 75-84, 85+ years);
sex (male, female); area of residence (urban, rural); quar-
tile of number of prescribed medications (4 categories);
level of care dependency (4 categories); number of
symptom complexes characterizing geriatric patients
( 4c a t e g o r i e s :0 ,1 - 2 ,3 - 4 ,5a n dm o r e )a n dn u m b e ro f
contacts to neurologists/psychiatrists in the incidence
year (5 categories: 0, 1-2, 3-5, 6-9, 10 and more). Next,
these variables were entered in a multivariate model
(model 2). Crude and adjusted odds ratios (OR) with 95%
confidence intervals (95% CI) were estimated.
We used SAS for Windows version 9.2 (SAS Institute
Inc., Cary, NC) for all statistical analyses.
The study was conducted according to the principles
expressed in the Declaration of Helsinki. We considered
the STROBE statement and the criteria of a national good
practice guideline [26,27]. According to the Good Practice
of Secondary Data Analysis, a national guideline for the
use of administrative databases, no approval of an ethical
committee is required [27].
Results
Characteristics of the study cohort
Baseline characteristics of the 1,848 patients with incident
dementia are shown in Table 2. Individuals in the cohort
are on average 78.7 years of age, and 47.6% are female.
Most of them live in an urban environment (72.0%).
Patients received on average 9.7 different medications
(interquartile range: 6-13), and 44.4% are assigned to one
of the three care levels. The most common symptom com-
plexes characterizing geriatric patients are severe visual
disturbances and hearing loss (47.7%), pain (46.1%), high
risk of complications (35.9%), depression and anxiety
(32.9%) and incontinence (24.0%). Virtually all patients
(92.0%) are classified as having at least one of these symp-
tom complexes. Altogether, 44.6% saw a neurologist or
psychiatrist at least once within the incidence year.
Table 1 List of the symptom complexes characterizing geriatric patients and their corresponding ICD-10 codes used in
this study (according to Borchelt et al. [25])
Symptom complexes characterizing geriatric
patients
ICD-10 codes
Immobility M96.8, M62.3, M62.5
Falls risk and dizziness R26, R29.81, R42, H81, H82
Incontinence R32, N39.3, N39.4, R15
Pressure ulcer L89, L97, I83.0, I83.2, L98.4
Malnutrition R64, E41, E43, E44
Disorders of fluid and electrolyte balance E86, E87, R60
Depression and anxiety F32, F33, F30, F31, F40, F41
Pain R52, R51, N23, R10, M54, K08.88, F62.80, H57.1, M79.6, M25.5, R07.0-R07.4, N64.4, H92.0, F45.4,
M75.8, K14.6
Neuropathies R20, G50-G59, G60-G64
Frailty R54
Severe visual disturbances and hearing loss H53, H54, H52.4, H25, H28, H90, H91
Medication problems Y57.9, X49.9
High risk of complications Z98, Z48, Z43, T79-T89, Z99.2, I48
Delayed convalescence Z54
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Baseline characteristics
Mean age, in years (SD) 78.7 (7.4)
Age groups, in years
65-74 30.6%
75-84 47.1%
85+ 22.3%
Sex
Male 52.4%
Female 47.6%
Area of residence*
Urban 72.0%
Rural 28.0%
Number of prescribed medications
Mean (SD) 9.7 (5.7)
Minimum (Q0, 0th percentile) 0
First quartile (Q1, 25th percentile) 6
Second quartile (Q2, median, 50th percentile) 9
Third quartile (Q3, 75th percentile) 13
Maximum (Q4, 100th percentile) 51
Level of care dependency
None 55.6%
1 20.7%
2 18.5%
3 5.2%
Symptom complexes characterizing geriatric patients
Severe visual disturbances and hearing loss 47.7%
Pain 46.1%
High risk of complications 35.9%
Depression and anxiety 32.9%
Incontinence 24.0%
Falls risk and dizziness 21.9%
Neuropathies 17.4%
Disorders of fluid and electrolyte balance 15.4%
Pressure ulcer 9.5%
Frailty 3.9%
Others (immobility, malnutrition, medication problems, delayed convalescence) 2.7%
Number of symptom complexes characterizing geriatric patients
0 8.0%
1-2 44.8%
3-4 34.5%
5+ 12.7%
Contacts to neurologists/psychiatrists
0 55.4%
1-2 9.0%
3-5 9.8%
6-9 12.2%
10+ 13.6%
* missing values for 2 patients for which classification into the urban or rural group was not possible
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The proportion of patients who received ChEIs was
13.0%. Concerning the first prescription of this drug class
in the incidence year, the majority was prescribed by neu-
rologists and psychiatrists (60.2%) as well as internists
and general practitioners (32.4%). The most frequently
used substance was donepezil (47.3%), followed by galan-
tamine (30.7%) and rivastigmine (22.0%).
Factors associated with prescribing
The proportions of patients with at least one prescription
of ChEIs stratified by covariates are presented in Table 3.
This table also shows results of the univariate and multi-
variate logistic regression analyses. Crude prevalences
and unadjusted odds ratios demonstrate that younger
patients were more likely to receive a prescription (65-74
v s .8 5 +y e a r s :1 8 . 9 %v s .6 . 6 % ;O R :3 . 3 2 ;9 5 %C I :2 . 1 3 -
5.18). When stratified for sex, living in a rural vs. urban
environment and for the number of prescribed medica-
tions, we found no significant differences in prescribing
patterns. Patients not assigned to the highest care level
were more likely to receive a prescription (e.g., no level
of dependency vs. level 3: 15.7% vs. 3.1%; OR: 5.83; 95%
CI: 1.82-18.61). The prescription prevalence decreased
with increasing numbers of geriatric symptoms com-
plexes (e.g., 0 vs. 5+ complexes: 22.3% vs. 7.7%). The
number of contacts to neurologists and psychiatrists also
had a strong influence on prescribing a ChEI. Only 4.2%
of patients with no contact to these specialists received a
prescription, this proportion increased to 37.3% in
Table 3 Logistic regression of factors associated with at least one prescription of cholinesterase inhibitors in the
incidence year and characteristics of ChEI users vs.non-users
Characteristics ChEI users
(n = 241)
Non-users
(n = 1,607)
Proportion of ChEI user
(n = 1,848)
Model 1
a)
ORcrude (95% CI)
Model 2
b)
ORadj (95% CI)
Age groups, in years
65-74 107 (44.4%) 459 (28.6%) 18.9% 3.32 (2.13-5.18) 1.41 (0.85-2.34)
75-84 107 (44.4%) 763 (47.5%) 12.3% 2.00 (1.29-3.10) 1.30 (0.81-2.11)
85+ 27 (11.2%) 385 (24.0%) 6.6% 1 1
Sex
Male 137 (56.8%) 832 (51.8%) 14.1% 1.23 (0.93-1.61) 0.89 (0.65-1.21)
Female 104 (43.2%) 775 (48.2%) 11.8% 1 1
Area of residence*
Urban 168 (69.7%) 1161 (72.3%) 12.6% 1 1
Rural 73 (30.3%) 444 (27.7%) 14.1% 1.14 (0.85-1.53) 1.48 (1.06-2.06)
Number of prescribed medications
Q1 (0-6) 90 (37.3%) 520 (32.4%) 14.8% 1.43 (0.97-2.10) 0.93 (0.58-1.49)
Q2 (7-9) 59 (24.5%) 352 (21.9%) 14.4% 1.38 (0.91-2.10) 1.03 (0.64-1.65)
Q3 (10-13) 48 (19.9%) 372 (23.1%) 11.4% 1.06 (0.69-1.64) 0.79 (0.49-1.28)
Q4 (14+) 44 (18.3%) 363 (22.6%) 10.8% 1 1
Level of care dependency
None 161 (66.8%) 866 (53.9%) 15.7% 5.83 (1.82-18.61) 5.35 (1.61-17.81)
1 41 (17.0%) 341 (21.2%) 10.7% 3.77 (1.14-12.44) 4.32 (1.26-14.75)
2 36 (14.9%) 306 (19.0%) 10.5% 3.69 (1.11-12.24) 3.97 (1.16-13.60)
3 3 (1.2%) 94 (5.8%) 3.1% 1 1
Symptom complexes characterizing geriatric patients
0 33 (13.7%) 115 (7.2%) 22.3% 3.46 (1.87-6.41) 4.23 (2.06-8.69)
1-2 120 (49.8%) 707 (44.0%) 14.5% 2.05 (1.22-3.44) 2.52 (1.41-4.50)
3-4 70 (29.0%) 568 (35.3%) 11.0% 1.49 (0.87-2.55) 1.59 (0.89-2.84)
5+ 18 (7.5%) 217 (13.5%) 7.7% 1 1
Contacts to neurologists/psychiatrists
0 43 (17.8%) 981 (61.0%) 4.2% 1 1
1-2 16 (6.6%) 151 (9.4%) 9.6% 2.42 (1.33-4.40) 2.53 (1.37-4.65)
3-5 44 (18.3%) 137 (8.5%) 24.3% 7.33 (4.64-11.57) 7.86 (4.88-12.66)
6-9 84 (34.9%) 141 (8.8%) 37.3% 13.59 (9.04-20.43) 14.05 (9.14-21.59)
10+ 54 (22.4%) 197 (12.3%) 21.5% 6.25 (4.07-9.60) 7.66 (4.85-12.11)
a) crude models
b) multivariate model adjusted for all other variables
* missing values for 2 patients for which classification into the urban or rural group was not possible
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those with 10+ contacts).
Odds ratios from the multivar i a t el o g i s t i cr e g r e s s i o n
model predicting at least one ChEI prescription are very
similar to those of the univariate analyses, with a few
exceptions. The effect of age was no longer statistically
significant when adjusting for all other covariates. Living
in a rural compared to an urban environment was asso-
ciated with a significant increase in the likelihood of
receiving ChEIs (OR: 1.48; 95% CI: 1.06-2.06), whereas in
the univariate model, no significant relationship had been
observed. The association of measures of geriatric
comorbidity (care levels and symptoms characterizing
geriatric patients) as well as the strong influence of con-
tacts to specialists on the chance of being prescribed a
ChEI remained in the multivariate analysis.
Discussion
Findings, comparison with other studies and
interpretation
In this study using administrative data of a cohort of
1,848 patients with incident dementia, we found that
contacts to specialists and measures of geriatric comor-
bidity are strongly associated with being prescribed a
ChEI. Older patients were less likely to receive a prescrip-
tion only in the univariate analysis, no significant rela-
tionship was observed in the multivariate model. Living
in a rural area had an influence on prescribing - only in
the multivariate model. The number of medications as a
measure of polypharmacy was n o ta s s o c i a t e dw i t hp r e -
scribing ChEI.
The univariate findings concerning age are in line with
the results of Franchi et al., [11] and Lucca et al. [13] who
both performed univariate analyses. The disappearance of
a significant effect of age on ChEI prescribing in the
adjusted model suggests that age as such is not an impor-
tant factor for the decision to prescribe. Instead the overall
clinical condition of a patient seems to have an influence.
We interpret the levels of care dependency and the num-
ber of symptom complexes characterizing geriatric
patients as proxies for functional and cognitive impair-
ment, and thus as proxies for frailty. Frailty is usually
described as a condition in which a critical number of spe-
cific impairments comprising mobility, strength loss and
weight loss occur simultaneously [28]. Regarding the find-
ing that measures of geriatric comorbidity have a strong
negative influence on ChEI prescription two extreme
interpretations are possible. On the one hand, persons
convinced of the benefits of ChEI might see a discrimina-
tion against the frail, dependent and ill. On the other
hand, persons with less optimistic expectations regarding
ChEI might see the cautious prescription of ChEI for these
patients as a sign of sensible consideration of probable
benefits and disadvantages. However, we still do not
exactly know how physicians develop their perceptions of
the benefits and drawbacks of antidementia drugs and
how they put them into practice.
We examined polypharmacy because it may lead to
adverse effects, drug-drug interactions, medication errors
as well as poor compliance [21,22] and physicians might
be cautious when prescribing ChEIs to vulnerable patients
with polypharmacy. The number of distinct medications is
often used as a comorbidity measure for predicting mor-
tality or hospitalizations [29,30]. The overall number of
medications was not associated with prescriptions of
ChEI. This might underline the hypothesis that the num-
ber of already prescribed medications has a much smaller
impact on the decision to prescribe ChEIs than the overall
clinical condition of a patient.
Besides the measures of geriatric comorbidity discussed
above we suggest that contacts to specialists have a strong
influence on being prescribed a ChEI. This has also been
shown in other German studies [10,14]. We assume that
the processes of further investigating the suspicion of
dementia (including a referral to a specialist) go hand in
hand with the considerations whether to prescribe ChEI
or not. Furthermore, in Germany, general practitioners
often involve specialists in order to disburden their own
prescription costs [31]. Accordingly, we found that 60% of
first prescriptions of ChEIs in our cohort were prescribed
by neurologists and psychiatrists.
Concerning urban-rural differences, we have recently
shown that the provision of primary practice seems to be
equally given in both areas but that rural patients are less
likely to consult neurologists or psychiatrists [18]. In rural
areas, the distance to such specialists can be far and the
transportation difficult for patients and caregivers which
might be one explanation for this result. We did not find
urban-rural differences in the crude model. After adjusting
for contacts to specialists in the multivariate analysis, the
likelihood of at least one prescription of a ChEI in the inci-
dence year was higher for patients in rural areas. This
finding is in line with Bohlken et al., who showed that the
prescribed doses of antidementia drugs per neurologist or
psychiatrist are higher in rural compared to urban areas
[32]. In summary, rural dementia patients less often see a
neurologist or psychiatrist than urban patients, but those
who do, have a greater chance to be prescribed a ChEI.
These points underline the importance of studying regio-
nal differences in health services utilization.
Strengths and limitations
Administrative data allow studying real-world utilization
patterns of unselected populations including also oldest
old, institutionalized, frail and cognitively impaired indi-
viduals, which represent a large majority of demented
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with selection bias concerning these factors [33,34].
Furthermore, field studies are much more expensive and
contain smaller and regional samples, whereas claims
data, like ours, contain information on a nationwide
population including urban and rural patients. However,
field studies can apply several diagnostic tests, physical
and psychological examinations performed by specially
trained professionals and therefore enable the researchers
to validate the diagnosis of dementia, which was not pos-
sible in our study. We were further unable to distinguish
between different types of dementia, since about half of
the cohort received ICD-codes for unspecified dementia
[10]. However, it is clinical reality in outpatient care in
Germany that treatment decisions in dementia often are
being made without having established an exact etiologi-
cal diagnosis. Furthermore, we do not have information
on dementia severity, which is assumed to be a relevant
factor for the decision to prescribe ChEIs or not. It has to
be kept in mind that we studied filled prescriptions and
there might be patient or caregiver factors that influence
the decision (not) to fill a prescription that are not cap-
tured in the data. We can not guarantee the validity of
our algorithm used to identify incident cases of dementia.
Since a health care contact and diagnostic awareness are
prerequisites for a diagnosis, especially patients with mild
dementia are less likely to be identified in claims data
[35]. This seems to be underlined by the fact that some
patients already received prescriptions of antidementia
drugs before their incidence year [10]. However, we
choose at least four dementia-free quarters followed by
three out of four consecutive quarters with codes indicat-
ing dementia to increase the validity of diagnoses by
avoiding transitory or erroneous diagnoses. On the other
hand, compared to a much broader definition of demen-
tia cases this results in a smaller sample size. Further-
more, these inclusion criteria allow us to study treatment
patterns in a more homogenous cohort of patients. Valid-
ity problems can also occur for the symptoms character-
izing geriatric patients which might lead to an
underestimation of these diagnoses. Updates of the corre-
sponding complexes have been recently published
(http://www.geriatrie-drg.de/dkger/main/gtmm-2010.
html) but we used the most recent version available dur-
ing the study period. Finally, there are several differences
between health insurance funds, for example with respect
to age, sex, socioeconomic position and morbidity
[36,37]. These differences might have an impact on the
utilization of health care resources. Thus extrapolations
of analyses of single funds to the whole German popula-
tion should be performed with caution. However, there
seems to be no obvious reason for treatment differences
in patients with dementia between different health insur-
ance funds.
Conclusions
We suggest that a lack of contacts to specialists and geria-
tric morbidity patterns reduce the chance for patients with
incident dementia of being prescribed a ChEI. It seems
that not age as such but the occurrence of care depen-
dency and geriatric comorbidities influences prescriptions.
Polypharmacy was not associated with prescriptions of
ChEI. This might further underline that the clinical condi-
tion of a patient plays an important role in the process of
decision making. Our findings give insight into the deci-
sion process whether or not to prescribe ChEI and point
at the need for further investigations of decision making
processes regarding medication, especially for a vulnerable
group such as dementia patients.
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